If you are currently receiving treatment for a gynecological cancer and have not yet filed a VA disability claim, file immediately. You are entitled to a 100% rating during active treatment. Every month without a filed claim is potential back pay you may not be able to recover. See the "Next Steps" section at the end of this guide — or start a free claim review now at /quick-qual/.
Women now make up nearly 17% of all veterans — the fastest-growing demographic in the VA system — yet for decades, their health conditions were systematically understudied and underrepresented in VA medical research. The result is a population of women veterans who have borne unique occupational health risks without the same research infrastructure that has supported male veteran conditions for generations.
The gynecological cancer risks facing women veterans stem from several documented military exposures:
Additionally, the stress of military service — particularly for women who served in predominantly male environments and disproportionately experienced MST — creates hormonal and immune disruption that research suggests may increase gynecological cancer risk through multiple pathways.
All of these factors have legal and evidentiary relevance to establishing service connection for gynecological cancers. This guide explains how each applies.
VA rates gynecological cancers under Diagnostic Codes 7615–7628 in 38 CFR Part 4, Schedule for Rating Disabilities, Subpart B. Here is the complete breakdown:
| DC | Condition | Active Disease Rating | Residual Approach |
|---|---|---|---|
| 7615 | Ovaries, malignant neoplasm of | 100% during active + 6 mo post-Tx | Rate by manifestation |
| 7616 | Uterus, malignant neoplasm of | 100% during active + 6 mo post-Tx | Rate by manifestation |
| 7617 | Uterus, removal of, complete or partial | N/A (surgical residual) | 30% or 50% based on residuals |
| 7619 | Ovaries, removal of | N/A (surgical residual) | Based on hormonal consequences |
| 7621 | Cervix, malignant neoplasm of | 100% during active + 6 mo post-Tx | Rate by manifestation |
| 7624 | Vagina, malignant neoplasm of | 100% during active + 6 mo post-Tx | Rate by manifestation |
| 7625 | Vulva and labia, malignant neoplasm of | 100% during active + 6 mo post-Tx | Rate by manifestation |
| 7628 | Gynecological conditions, other | 100% if malignant, during active + 6 mo post-Tx | Rate by manifestation |
The pattern is consistent: all active gynecological malignancies receive a 100% rating during treatment and for 6 months post-treatment. The complexity and the opportunity arise in what happens after that window — residuals rating — which is where many veterans lose significant compensation through inadequate planning.
Under 38 CFR § 4.115b, any veteran with an active malignancy that is service-connected receives a 100% disability rating. This applies to all gynecological cancers: ovarian, uterine, cervical, vaginal, vulvar, fallopian tube, and other gynecological malignancies.
"Active" means the cancer is currently being treated or has not yet been confirmed in remission. This includes:
The 100% rating translates to the full disability compensation rate, which in 2026 ranges from approximately $3,737/month (100% with no dependents) to $4,280+/month with a spouse and children. For veterans who have been paying out of pocket for cancer treatment and facing lost income, this compensation can be life-changing — but only if the claim is filed.
Many women veterans delay filing because they are focused on treatment, or because they believe they can only claim benefits after treatment ends. This is a costly misconception. File immediately upon diagnosis — your effective date for back pay is the date VA receives your claim. Every month of delay is compensation you cannot recover retroactively unless you have a clear and unmistakable error (CUE) basis.
Under 38 CFR § 4.115b, the 100% malignant neoplasm rating continues for 6 months following the cessation of active treatment. "Cessation of active treatment" is typically the date of the final chemotherapy infusion, the last day of radiation, or the date post-surgical care transitions to surveillance/monitoring.
After the 6-month window, VA conducts a rating reduction review. At this point, the rating is no longer based on the active malignancy — it shifts to rating residuals, the lasting effects of the cancer and its treatment.
During the 6-month post-treatment period, you should actively prepare your residuals claims. This means:
If you file residuals claims only after VA sends a notice proposing to reduce your 100% rating, you may face a gap in compensation. File residuals documentation during the 6-month period so VA processes both simultaneously. A VA-accredited attorney or claims agent can help ensure the transition is managed correctly.
Under 38 CFR § 3.303, direct service connection requires: a current diagnosis, an in-service event or incurrence, and a nexus. For gynecological cancers, the challenge is often the latency period — cancer typically develops years or decades after the causative exposure. A well-crafted nexus letter explains the known latency periods for specific cancers and how in-service exposures fall within the scientific model.
VA maintains a list of conditions that are presumptively service-connected based on documented exposure patterns, without requiring veterans to prove individual causation. Gynecological cancers can qualify as presumptives under several frameworks, most importantly the PACT Act (discussed below).
Under 38 CFR § 3.306, if a pre-existing gynecological condition (such as precancerous cervical dysplasia, HPV, or benign ovarian conditions) was materially aggravated by military service — through delayed treatment, toxic exposures, or hormonal disruption from service stress — service connection may be established for the resulting malignancy.
The Sergeant First Class Heath Robinson Honoring our Promise to Address Comprehensive Toxics (PACT) Act, signed in August 2022, represents the most significant expansion of veteran cancer benefits in decades. For women veterans with gynecological cancers, PACT Act presumptives may completely eliminate the need to prove a specific nexus — if the qualifying service and exposure history is established.
Veterans who served in Southwest Asia (including Iraq, Afghanistan, Syria, Djibouti), Uzbekistan, Somalia, or other covered areas after August 2, 1990, may be eligible for cancer presumptives under the airborne hazard/open burn pit framework. The PACT Act directs VA to presume that any cancer that appears after qualifying service is related to that service — including gynecological cancers.
This is a remarkable expansion: it means a woman veteran who served in Iraq and later developed ovarian cancer does not need to prove that burn pit exposure specifically caused her ovarian cancer. She needs to show qualifying service, qualifying exposure area, and the cancer diagnosis. VA presumes the connection.
Veterans and their family members who lived or worked at Marine Corps Base Camp Lejeune or Marine Corps Air Station New River, North Carolina, for not less than 30 days between August 1, 1953, and December 31, 1987, may qualify for presumptive service connection for several cancers. The contaminants in the water supply — trichloroethylene, perchloroethylene, benzene, and vinyl chloride — are classified carcinogens with documented links to multiple cancer types.
VA has recognized specific cancers as presumptively connected to Camp Lejeune water exposure. Women veterans (and dependents of veterans) who qualify should check whether their specific cancer is on VA's current presumptive list, which has been expanded multiple times since the initial Camp Lejeune legislation.
Veterans who participated in nuclear testing programs (nuclear weapons testing, occupation of Hiroshima or Nagasaki), or who were exposed to ionizing radiation during service, can qualify for cancer presumptives under 38 CFR § 3.309(d). Gynecological cancers, including ovarian and uterine cancer, are on the list of radiogenic cancers that can be presumptively connected for veterans with documented radiation exposure.
| PACT Act Pathway | Qualifying Service | Relevant Gynecological Cancers |
|---|---|---|
| Burn pit / airborne hazards | Post-8/2/1990 in covered SW Asia areas | All malignancies, including ovarian, cervical, uterine, vaginal |
| Camp Lejeune water | 30+ days at Lejeune/MCAS New River, 1953–1987 | Per VA's current presumptive list |
| Radiation exposure | Documented ionizing radiation exposure | Ovarian, uterine, other radiogenic cancers (38 CFR § 3.309(d)) |
| Agent Orange | Vietnam-era service, qualifying exposure areas | Per VA's AO presumptive list |
See our guide on the PACT Act presumptive conditions for full details on qualifying service parameters.
Cervical cancer is rated under DC 7621 — Cervix, malignant neoplasm of. During active treatment (surgery, chemotherapy, radiation, or immunotherapy): 100%. For 6 months following cessation of active treatment: 100%. After 6 months: rated by residuals.
Cervical cancer is caused by persistent high-risk HPV infection. The connection to military service can run through several pathways:
The MST-cervical cancer nexus is particularly important. Women who experienced MST are at elevated risk for both HPV exposure and for impaired immune clearance of HPV. For veterans with service-connected PTSD based on MST, a secondary service connection argument for cervical cancer — through immune disruption — is medically supportable with the right expert opinion.
Ovarian cancer is rated under DC 7615 — Ovaries, malignant neoplasm of. The same 100%-during-active-treatment, 100%-for-6-months-post-treatment rule applies. After the 6-month window, residuals are rated by manifestation — the lasting functional consequences of oophorectomy, chemotherapy, and other treatment components.
Ovarian cancer has a less clearly defined single environmental cause than cervical cancer, but several military-specific exposure pathways are recognized:
Uterine cancer (including endometrial cancer, the most common type) is rated under DC 7616 — Uterus, malignant neoplasm of. Active treatment = 100%. Six months post-treatment = 100%. After 6-month period = rated by residuals, primarily under DC 7617 (removal of uterus) if hysterectomy was performed.
Uterine/endometrial cancer is primarily driven by excess estrogen exposure and obesity. For women veterans, military service can connect to uterine cancer through several routes:
If treatment included hysterectomy (full or partial), the residual disability is rated under DC 7617 — Uterus, removal of, complete or partial:
| Rating | Criteria |
|---|---|
| 50% | Complete removal with oophorectomy and resulting severe menopausal symptoms not relieved by treatment |
| 30% | Complete removal without oophorectomy, or with menopausal symptoms controlled by treatment |
| 10% | Partial removal |
Veterans who had complete hysterectomy with bilateral salpingo-oophorectomy (removal of both ovaries and fallopian tubes) and experience significant menopausal symptoms — including bone density loss, cardiovascular changes, cognitive effects, severe hot flashes, vaginal atrophy — should target the 50% rating and document surgical menopause symptoms explicitly.
Vaginal cancer (DC 7624) and vulvar cancer (DC 7625) are less common than ovarian, uterine, or cervical cancers, but women veterans with these diagnoses have the same entitlement to the 100% active treatment rating and post-treatment residuals claims.
Vaginal and vulvar cancers are frequently associated with HPV infection (especially vulvar cancer) or may arise as late complications of cervical cancer radiation treatment. Veterans who received pelvic radiation for cervical cancer and later develop vaginal cancer may have a secondary connection claim for the vaginal cancer as a radiation sequela.
The residuals phase of a gynecological cancer claim is where careful documentation makes the difference between 20% total compensation and 80%+ combined. Here is the complete residuals landscape:
| Surgery Type | Primary Residual DC | Rating Potential |
|---|---|---|
| Complete hysterectomy | DC 7617 | 30–50% |
| Bilateral oophorectomy | DC 7619 + menopausal sequelae | Variable by symptoms |
| Lymph node dissection → lymphedema | DC 7199 (lymphatic conditions) | 10–60% |
| Bladder involvement / cystectomy | DC 7519 (genitourinary) | 10–100% |
Cancer diagnosis and treatment — especially for gynecological cancers that affect fertility, sexual health, and body image — is associated with high rates of depression, anxiety, PTSD, and adjustment disorder. These conditions are ratable as secondary conditions when they develop in the context of a service-connected cancer:
The mental health rating schedule rates based on GAF (Global Assessment of Functioning) score and occupational/social impairment. A veteran with significant depression and functional impairment secondary to cancer can receive 50–100% for mental health secondary conditions alone, on top of the somatic residuals rating.
For the active disease claim with PACT Act presumptive, a nexus letter is typically not required — the presumption eliminates the nexus requirement. But nexus letters are still needed for:
Nexus Letters for Cancer Residuals
The residuals phase is where the most compensation is won or lost. REE Medical works with oncologists, gynecologists, and other specialists who can provide comprehensive nexus opinions connecting each treatment residual to your service-connected cancer — covering neuropathy, hormonal consequences, surgical residuals, and mental health impacts in a single coordinated review.
Learn About REE Medical's Cancer Residuals Nexus Letters →claim.vet may receive a referral fee if you use this link. Veterans never pay more.
Transgender and non-binary veterans may face additional complexity when navigating gynecological cancer claims, but the legal entitlement is clear: VA evaluates disability claims based on diagnosed medical conditions and their relationship to service, not on gender designation.
Transgender men and non-binary veterans (assigned female at birth) who retain female reproductive organs and develop gynecological cancer after service are entitled to VA disability benefits on the same basis as any other veteran. The service connection pathways, rating criteria, and residuals strategies described in this guide apply fully.
Transgender women who served in the military may, depending on their medical history, have conditions related to retained anatomy that qualify for certain disability ratings — including prostate-related conditions. Consult a VA-accredited attorney for guidance on the specific intersection of gender identity and applicable rating codes.
VA's LGBTQ+ Veteran Care program at patientcare.va.gov/LGBT offers resources and designated providers who can help LGBTQ+ veterans navigate both clinical care and the claims process with appropriate sensitivity.
Here is the step-by-step sequence for a gynecological cancer VA disability claim:
You served. You were exposed. You developed cancer. You deserve 100% during treatment — and substantial residuals compensation after. Start your free claim review today — no phone calls required.
Start My Free Claim Review — No Phone Required →Editorial Standards: Written by Marcus J. Webb, veterans benefits researcher. Verified against current 38 CFR regulations, PACT Act provisions, and VA adjudication guidelines. Last reviewed: July 2026. Not legal advice — for representation, talk to a VA-accredited attorney.